Potent induction of humoral and cellular immunity after bivalent BA.4/5 mRNA vaccination in dialysis patients with and without history of SARS-CoV-2 infection

• DOI: 10.1101/2023.08.13.23294045
• Publication Date: 2023-08-16T15:45:29Z
• Authors: Saskia Bronder; Janine Mihm; Rebecca Urschel; Verena Klemis; Tina Schmidt; Stefanie Marx; Amina Abu-Omar; Franziska Hielscher; Candida Guckelmus; Marek Widera; Urban Sester; Martina Sester
• Keywords: Bivalent (engine); Cellular immunity; Humoral immunity

Abstract Knowledge on immunogenicity of the bivalent Omicron BA.4/5 vaccine in dialysis patients and effect a previous infection is limited. Therefore, vaccine-induced humoral cellular immunity was analyzed immunocompetent controls with without prior infection. In an observational study, 33 58 matched for age, sex status were recruited. Specific IgG, neutralizing antibody activity towards spike-antigen from parental SARS-CoV-2 subvariants BA.1, BA.2 before 13-18 days after vaccination. The led to significant induction titers, specific CD4 CD8 T-cell levels. Neutralizing strain highest, whereas levels spike did not differ indicating substantial cross-reactivity. Dialysis had significantly higher spike-specific lower CTLA-4 expression compared infection-naïve patients. When controls, no differences observed between individuals Among infected individuals, antibodies controls. Vaccination overall well tolerated both less adverse events among conclusion, our study provide any evidence impaired Unlike even associated T cells, which may reflect prolonged encounter antigen during Translational statement uremic immunodeficiency are at increased risk infectious complications have been shown insufficiently respond first doses COVID-19 vaccines. Bivalent vaccines now recommended, although knowledge limited this patient group. We show that pronounced antibodies, similar magnitude non-infected Despite some infection, data do